What does the future hold for the management of chronic heart failure?

Emilio Vanoli, Philip B. Adamson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sudden cardiac death (SCD) represents a major challenge in managing chronic heart failure (CHF). There is extensive evidence of the antifibrillatory action of beta-blockers and their ability to prevent SCD in patients with CHF and left ventricular (LV) dysfunction following myocardial infarction (MI). In contrast, angiotensin-converting enzyme-inhibitors have minimal effects on SCD risk, reducing mortality primarily by preventing or delaying pump failure. The mechanisms by which beta-blockers reduce lethal arrhythmias and thereby prevent SCD mostly reflect blockade of the beta1-subtype. Dog models have been used to investigate ventricular remodelling and arrhythmogenesis after MI; dogs with chronic ischaemic LV dysfunction susceptible to SCD have depressed vagal and elevated sympathetic control of heart rate coupled with abnormal repolarization. Furthermore, susceptibility to SCD appears to be associated with non-uniform catecholamine release within the left ventricle. Cardiac nerve sprouting and sympathetic hyperinnervation consequent to ischaemic neural damage are important co-factors causing ventricular electrical dyshomogeneity and, thus, malignant tachyarrhythmias and SCD. Regulating nerve growth factor and growth-associated protein 43 expression after MI might provide a means of controlling arrhythmias and preventing SCD. An intriguing possibility might be the prevention of cardiac norepinephrine spillover by means of gene therapy to increase expression of the norepinephrine transporter molecule uptake-1. At this stage, the evidence from clinical trials, and especially that from Cardiac Insufficiency Bisoprolol Study III, strongly supports the use of selective beta-adrenergic blockade as a primary intervention in the management of patients with CHF.

Original languageEnglish
JournalEuropean Heart Journal, Supplement
Volume8
Issue numberC
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Sudden Cardiac Death
Heart Failure
Myocardial Infarction
Left Ventricular Dysfunction
Cardiac Arrhythmias
Bisoprolol
Dogs
Norepinephrine Plasma Membrane Transport Proteins
GAP-43 Protein
Ventricular Remodeling
Nerve Growth Factor
Angiotensin-Converting Enzyme Inhibitors
Tachycardia
Genetic Therapy
Adrenergic Agents
Heart Ventricles
Catecholamines
Norepinephrine
Heart Rate
Clinical Trials

Keywords

  • Adrenergic blockade
  • Autonomic nervous system
  • Heart failure
  • Sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

What does the future hold for the management of chronic heart failure? / Vanoli, Emilio; Adamson, Philip B.

In: European Heart Journal, Supplement, Vol. 8, No. C, 06.2006.

Research output: Contribution to journalArticle

@article{1105734b99de47909751526521bd1deb,
title = "What does the future hold for the management of chronic heart failure?",
abstract = "Sudden cardiac death (SCD) represents a major challenge in managing chronic heart failure (CHF). There is extensive evidence of the antifibrillatory action of beta-blockers and their ability to prevent SCD in patients with CHF and left ventricular (LV) dysfunction following myocardial infarction (MI). In contrast, angiotensin-converting enzyme-inhibitors have minimal effects on SCD risk, reducing mortality primarily by preventing or delaying pump failure. The mechanisms by which beta-blockers reduce lethal arrhythmias and thereby prevent SCD mostly reflect blockade of the beta1-subtype. Dog models have been used to investigate ventricular remodelling and arrhythmogenesis after MI; dogs with chronic ischaemic LV dysfunction susceptible to SCD have depressed vagal and elevated sympathetic control of heart rate coupled with abnormal repolarization. Furthermore, susceptibility to SCD appears to be associated with non-uniform catecholamine release within the left ventricle. Cardiac nerve sprouting and sympathetic hyperinnervation consequent to ischaemic neural damage are important co-factors causing ventricular electrical dyshomogeneity and, thus, malignant tachyarrhythmias and SCD. Regulating nerve growth factor and growth-associated protein 43 expression after MI might provide a means of controlling arrhythmias and preventing SCD. An intriguing possibility might be the prevention of cardiac norepinephrine spillover by means of gene therapy to increase expression of the norepinephrine transporter molecule uptake-1. At this stage, the evidence from clinical trials, and especially that from Cardiac Insufficiency Bisoprolol Study III, strongly supports the use of selective beta-adrenergic blockade as a primary intervention in the management of patients with CHF.",
keywords = "Adrenergic blockade, Autonomic nervous system, Heart failure, Sudden death",
author = "Emilio Vanoli and Adamson, {Philip B.}",
year = "2006",
month = "6",
doi = "10.1093/eurheartj/sul014",
language = "English",
volume = "8",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "C",

}

TY - JOUR

T1 - What does the future hold for the management of chronic heart failure?

AU - Vanoli, Emilio

AU - Adamson, Philip B.

PY - 2006/6

Y1 - 2006/6

N2 - Sudden cardiac death (SCD) represents a major challenge in managing chronic heart failure (CHF). There is extensive evidence of the antifibrillatory action of beta-blockers and their ability to prevent SCD in patients with CHF and left ventricular (LV) dysfunction following myocardial infarction (MI). In contrast, angiotensin-converting enzyme-inhibitors have minimal effects on SCD risk, reducing mortality primarily by preventing or delaying pump failure. The mechanisms by which beta-blockers reduce lethal arrhythmias and thereby prevent SCD mostly reflect blockade of the beta1-subtype. Dog models have been used to investigate ventricular remodelling and arrhythmogenesis after MI; dogs with chronic ischaemic LV dysfunction susceptible to SCD have depressed vagal and elevated sympathetic control of heart rate coupled with abnormal repolarization. Furthermore, susceptibility to SCD appears to be associated with non-uniform catecholamine release within the left ventricle. Cardiac nerve sprouting and sympathetic hyperinnervation consequent to ischaemic neural damage are important co-factors causing ventricular electrical dyshomogeneity and, thus, malignant tachyarrhythmias and SCD. Regulating nerve growth factor and growth-associated protein 43 expression after MI might provide a means of controlling arrhythmias and preventing SCD. An intriguing possibility might be the prevention of cardiac norepinephrine spillover by means of gene therapy to increase expression of the norepinephrine transporter molecule uptake-1. At this stage, the evidence from clinical trials, and especially that from Cardiac Insufficiency Bisoprolol Study III, strongly supports the use of selective beta-adrenergic blockade as a primary intervention in the management of patients with CHF.

AB - Sudden cardiac death (SCD) represents a major challenge in managing chronic heart failure (CHF). There is extensive evidence of the antifibrillatory action of beta-blockers and their ability to prevent SCD in patients with CHF and left ventricular (LV) dysfunction following myocardial infarction (MI). In contrast, angiotensin-converting enzyme-inhibitors have minimal effects on SCD risk, reducing mortality primarily by preventing or delaying pump failure. The mechanisms by which beta-blockers reduce lethal arrhythmias and thereby prevent SCD mostly reflect blockade of the beta1-subtype. Dog models have been used to investigate ventricular remodelling and arrhythmogenesis after MI; dogs with chronic ischaemic LV dysfunction susceptible to SCD have depressed vagal and elevated sympathetic control of heart rate coupled with abnormal repolarization. Furthermore, susceptibility to SCD appears to be associated with non-uniform catecholamine release within the left ventricle. Cardiac nerve sprouting and sympathetic hyperinnervation consequent to ischaemic neural damage are important co-factors causing ventricular electrical dyshomogeneity and, thus, malignant tachyarrhythmias and SCD. Regulating nerve growth factor and growth-associated protein 43 expression after MI might provide a means of controlling arrhythmias and preventing SCD. An intriguing possibility might be the prevention of cardiac norepinephrine spillover by means of gene therapy to increase expression of the norepinephrine transporter molecule uptake-1. At this stage, the evidence from clinical trials, and especially that from Cardiac Insufficiency Bisoprolol Study III, strongly supports the use of selective beta-adrenergic blockade as a primary intervention in the management of patients with CHF.

KW - Adrenergic blockade

KW - Autonomic nervous system

KW - Heart failure

KW - Sudden death

UR - http://www.scopus.com/inward/record.url?scp=33750094540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750094540&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/sul014

DO - 10.1093/eurheartj/sul014

M3 - Article

AN - SCOPUS:33750094540

VL - 8

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - C

ER -